Active Diabetes, Hormones & Metabolism Genetics & Molecular Biology

Non-coding mutations in congenital hyperinsulinism: deciphering the role of gene dysregulation in human disease

In plain English

AI plain-English summary

A single DNA typo in a non-coding region can switch on a gene that should stay silent in insulin-making cells, triggering dangerously low blood sugar in newborns. This matters because congenital hyperinsulinism—where the pancreas pumps out too much insulin—can cause brain damage if not caught early. Current treatments are limited, and many patients still need their pancreas partly removed. The problem is that most genetic studies focus on protein-coding genes, but the real culprits may lie in the vast non-coding stretches of DNA that control when and where genes turn on. The researcher has already found one such mutation that reactivates *HK1*, a gene normally shut off in beta-cells. Now, using a unique cohort of ~2000 patients with no known cause, they will scan for similar regulatory glitches. If successful, this work could reveal new drug targets for hyperinsulinism—perhaps molecules that re-silence these rogue genes without surgery. More broadly, it will demonstrate how non-coding mutations drive disease, opening a new avenue for diagnosing and treating other monogenic conditions where coding mutations have come up empty. This is fundamental science with a clear clinical horizon.

View original technical description
This research will use novel insights from genomic analysis of individuals with congenital hyperinsulinism to provide new mechanistic understanding of the regulation of insulin secretion. Through preliminary studies I have identified non-coding mutations that affect the regulation of HK1, a housekeeping gene which is silenced within the beta-cell. These mutations pinpoint the first element to be discovered that regulates beta-cell specific silencing and highlights the role of ‘disallowed’ genes in pathophysiology. To discover further regulatory mutations affecting the expression of a beta-cell ‘disallowed’ gene I will integrate genomic data with epigenomic annotation in my unique cohort of ~2000 hyperinsulinism patients with known causes excluded. I will study the impact of mutations in affected pancreatic tissue to gain insights into 1) the mechanism(s) by which they disrupt insulin-secretion and 2) the regulatory networks that are critical for maintaining tissue-specific suppression of genes. The results from these studies may be leveraged to discover novel targets to better treat hyperinsulinism and will improve knowledge of the role of the non-coding genome. This will be important for genetic discovery in other monogenic conditions where the major focus has been on the discovery of coding mutations in genes highly expressed within the disease tissue.

View the original record at the funder ↗

Researchers

Sarah Flanagan (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Wellcome Trust Senior Research Fellowship
Applying the power of genetics to increase knowledge of underlying mechanisms of recessively inherited congenital hyperinsulinism.
Multicellular regulation of insulin secretion from pancreatic islets
Modelling human pancreatic beta cell enhancer function in diabetes
Title: Understanding the molecular mechanisms of hyperinsulinaemic hypoglycaemia and developing novel therapies

Original classification

Senior Research Fellowship

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.